(Q37784558)

23 August 2017

title

Bacteriophages as potential new therapeutics to replace or supplement antibiotics (English)

1 reference

23 August 2017

0 references

1 reference

Mzia Kutateladze

1

1 reference

23 August 2017

Revaz Adamia

2

1 reference

23 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20810181

4 July 2024

publication date

31 August 2010

1 reference

full work available at URL

23 August 2017

https://api.elsevier.com/content/article/PII:S016777991000137X?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.TIBTECH.2010.08.001

https://api.elsevier.com/content/article/PII:S016777991000137X?httpAccept=text/plain

4 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.TIBTECH.2010.08.001

4 July 2024

published in

Trends in Biotechnology

1 reference

23 August 2017

volume

28

1 reference

23 August 2017

issue

12

1 reference

23 August 2017

page(s)

591-595

1 reference

Penicillin-resistant Streptococcus pneumoniae: selection by both beta-lactam and non-beta-lactam antibiotics

23 August 2017

cites work

7

1 reference

https://api.crossref.org/works/10.1016/J.TIBTECH.2010.08.001

Sitafloxacin in the treatment of patients with infections caused by vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus

4 July 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.TIBTECH.2010.08.001

A hospital epidemic of vancomycin-resistant Enterococcus: risk factors and control

4 July 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.TIBTECH.2010.08.001

Vancomycin-resistant enterococci: mechanisms and clinical observations

4 July 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.TIBTECH.2010.08.001

Severe multiresistant Salmonella typhimurium systemic infections in Central Africa--clinical features and treatment in a paediatric department

4 July 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.TIBTECH.2010.08.001

Relation between induction of the mar operon and cyclohexane tolerance and reduction in fluoroquinolone susceptibility in Salmonella spp

4 July 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.TIBTECH.2010.08.001

Effect of exposure to fluoroquinolones and beta-lactams on the in vitro activity of other groups of antibiotics in Salmonella spp.

4 July 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.TIBTECH.2010.08.001

Activity of phenothiazines against antibiotic-resistant Mycobacterium tuberculosis: a review supporting further studies that may elucidate the potential use of thioridazine as anti-tuberculosis therapy.

4 July 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.TIBTECH.2010.08.001

Inhibition of the respiration of multi-drug resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: potential use for initial therapy of freshly diagnosed tuberculosis

4 July 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.TIBTECH.2010.08.001

Phage choice, isolation, and preparation for phage therapy.

4 July 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.TIBTECH.2010.08.001

Designing phage therapeutics

4 July 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.TIBTECH.2010.08.001

STAPHAGE LYSATE THERAPY IN CHRONIC STAPHYLOCOCCAL INFECTIONS

4 July 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.TIBTECH.2010.08.001

Phage therapy experience at the Eliava Institute

4 July 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.TIBTECH.2010.08.001

4 July 2024

Bacteriophage therapy

27

1 reference

https://api.crossref.org/works/10.1016/J.TIBTECH.2010.08.001

Phage Therapy in Clinical Practice: Treatment of Human Infections

4 July 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.TIBTECH.2010.08.001

Phage-Antibiotic Synergy (PAS): beta-lactam and quinolone antibiotics stimulate virulent phage growth

4 July 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.TIBTECH.2010.08.001

Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials

4 July 2024

33

1 reference

https://api.crossref.org/works/10.1016/J.TIBTECH.2010.08.001

A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa ; a preliminary report of efficacy

4 July 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.TIBTECH.2010.08.001

Results of bacteriophage treatment of suppurative bacterial infections. III. Detailed evaluation of the results obtained in further 150 cases

4 July 2024

37

1 reference

https://api.crossref.org/works/10.1016/J.TIBTECH.2010.08.001

Preventive value of dried dysentery bacteriophage

4 July 2024

38

1 reference

https://api.crossref.org/works/10.1016/J.TIBTECH.2010.08.001

4 July 2024

Identifiers

1 reference

23 August 2017

1 reference